Innovation1 Biotech Stock Cash Flow From Operations
| IVBT Stock | USD 0 0.00 0.00% |
Innovation1 Biotech fundamentals help investors to digest information that contributes to Innovation1 Biotech's financial success or failures. It also enables traders to predict the movement of Innovation1 OTC Stock. The fundamental analysis module provides a way to measure Innovation1 Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovation1 Biotech otc stock.
Innovation1 |
Innovation1 Biotech OTC Stock Cash Flow From Operations Analysis
Innovation1 Biotech's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Innovation1 Biotech Cash Flow From Operations | (3.13 M) |
Most of Innovation1 Biotech's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovation1 Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Innovation1 Biotech has (3.13 Million) in Cash Flow From Operations. This is 100.59% lower than that of the Healthcare sector and 105.0% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 100.32% higher than that of the company.
Innovation1 Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Innovation1 Biotech's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Innovation1 Biotech could also be used in its relative valuation, which is a method of valuing Innovation1 Biotech by comparing valuation metrics of similar companies.Innovation1 Biotech is currently under evaluation in cash flow from operations category among its peers.
Innovation1 Fundamentals
| Return On Equity | -1.79 | |||
| Return On Asset | -0.0781 | |||
| Current Valuation | 1.83 M | |||
| Shares Outstanding | 20.02 M | |||
| Shares Owned By Insiders | 74.66 % | |||
| Price To Earning | 0.01 X | |||
| Price To Book | 0.05 X | |||
| Gross Profit | (17 K) | |||
| EBITDA | (38.33 M) | |||
| Net Income | (40.88 M) | |||
| Cash And Equivalents | 636.16 K | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 554.4 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | 0.10 X | |||
| Cash Flow From Operations | (3.13 M) | |||
| Earnings Per Share | 5.54 X | |||
| Beta | 5.08 | |||
| Market Capitalization | 4.5 M | |||
| Total Asset | 43.96 M | |||
| Z Score | 4.8 | |||
| Net Asset | 43.96 M |
About Innovation1 Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovation1 Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovation1 Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovation1 Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.